Nightingale Health: Market opening will soon be tested
Nightingale’s growth journey has clearer guidelines thanks to revised strategy. Although the coming year will not yet be a turning point business wise for the company, the Terveystalo customer reference that is being built and new international reference that are sought still have conditions to generate evidence of successful commercial use of the company’s technology. The visibility of success still remains weak and we stay on the sidelines waiting for the risk/return ratio to strengthen.
Nightingale Health
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures29.09.2023
2023 | 24e | 25e | |
---|---|---|---|
Omsætning | 4,2 | 5,0 | 8,5 |
vækst-% | 80,80 % | 19,62 % | 69,00 % |
EBIT (adj.) | -18,5 | -20,0 | -18,7 |
EBIT-% (adj.) | -442,95 % | -399,75 % | -220,83 % |
EPS (adj.) | -0,30 | -0,32 | -0,29 |
Udbytte | 0,00 | 0,00 | 0,00 |
Udbytte % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | 0,77 | - | - |